GO:0005898 interleukin-13 receptor complex: Components, Assembly and Research Methods, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005898 (interleukin-13 receptor complex) is a cell-surface protein complex that binds interleukin-13 and consists of the interleukin-13 receptor alpha1 chain (IL13RA1) and the interleukin-4 receptor alpha chain (IL4R).
• The complex is a shared signaling hub for both IL-4 and IL-13, explaining the pleiotropy of type 2 cytokine responses.
• Assembly is stepwise: IL-13 first binds IL13RA1 with high affinity, then recruits IL4R to form the signaling-competent ternary complex.
• The complex signals mainly through JAK-STAT6 and IRS-1/2 pathways, driving allergic inflammation, mucus production, and tissue remodeling.
• Dysregulated interleukin-13 receptor complex activity is implicated in asthma, atopic dermatitis, cholangiocyte dysfunction, cardiac remodeling, and lymphoma risk under dupilumab therapy.
• CRISPR knockout, point-mutation, knock-in, and overexpression models are essential to dissect IL13RA1/IL4R contributions to disease and to validate therapeutic targets.
Description
The interleukin-13 receptor complex (GO:0005898) is a heteromeric cell-surface receptor that binds the cytokine interleukin-13 (IL-13) and initiates intracellular signaling. According to the Gene Ontology, it is composed of two chains: the interleukin-13 receptor alpha1 chain (IL13RA1) and the interleukin-4 receptor alpha chain (IL4R). This complex is a central node in type 2 immunity and is a major pharmacological target in allergic and fibrotic diseases. Researchers study GO:0005898 because it integrates signals from two related cytokines, IL-4 and IL-13, and thereby controls diverse outputs such as immunoglobulin class switching, goblet cell metaplasia, and alternative macrophage activation. Structural and biochemical work has shown that IL-13 binding to IL13RA1 creates a composite surface that recruits IL4R, forming a ternary complex capable of activating JAK-STAT and IRS pathways. This mechanism explains why a single receptor complex can mediate both overlapping and distinct functions of IL-4 and IL-13. Beyond allergy, the complex has been linked to cholangiocyte secretion, cardiac remodeling after ischemic injury, and even cutaneous T cell lymphoma following dupilumab therapy. Understanding its assembly, regulation, and downstream effectors is therefore critical for developing safer and more effective therapeutics.
interleukin-13 receptor complex At A Glance
| GO ID | GO:0005898 |
|---|---|
| GO term | interleukin-13 receptor complex |
| Ontology | cellular_component |
| Synonym | IL-13 receptor complex |
| Definition | A protein complex that binds interleukin-13; consists of two chains, interleukin-13 receptor alpha1 chain and interleukin-4 receptor alpha chain. |
| Major function | Binds IL-13 and transduces signals via JAK-STAT and IRS pathways. |
| Subunits | IL13RA1 and IL4R. |
| Ligand | Interleukin-13 (IL-13). |
| Associated diseases | Asthma, atopic dermatitis, cholangiocyte dysfunction, cardiac remodeling, lymphoma risk. |
What Is GO:0005898?
The interleukin-13 receptor complex is a protein complex located at the cell surface that specifically binds interleukin-13. It consists of two essential chains: interleukin-13 receptor alpha1 chain (IL13RA1) and interleukin-4 receptor alpha chain (IL4R). This heterodimeric assembly is required for high-affinity IL-13 binding and for initiating intracellular signaling cascades.
Why Is interleukin-13 receptor complex Important in Cell Biology?
The interleukin-13 receptor complex is a critical signaling hub for type 2 immune responses and a validated drug target. Blocking this complex with dupilumab, an IL-4Rα antagonist, has transformed treatment of atopic dermatitis and asthma, but rare lymphoma cases highlight the need for deeper mechanistic understanding. The complex also operates in non-immune tissues, where it regulates cholangiocyte TMEM16A expression and biliary secretion, and in the heart, where IL-4Rα+ macrophages drive adverse remodeling. Thus, GO:0005898 is important for both immunology and organ physiology.
• Central mediator of IL-13 and IL-4 signaling in allergy and asthma.
• Target of dupilumab and other biologics in atopic dermatitis and asthma.
• Regulates cholangiocyte TMEM16A and biliary secretion.
• Drives adverse cardiac remodeling via IL-4Rα+ macrophages.
• Linked to cutaneous T cell lymphoma risk after dupilumab therapy.
• Involved in eosinophil-mediated vascular calcification through BMP receptor crosstalk.
• Mouse Il13ra1 gene characterization provides model system insights.
• Key for understanding cytokine receptor pleiotropy and shared signaling.
• Potential target in fibrotic and inflammatory diseases beyond allergy.
• Essential for designing selective inhibitors of IL-13 versus IL-4 pathways.
Structure and Composition of interleukin-13 receptor complex
IL13RA1: the primary IL-13 binding chain
In simple terms: IL13RA1 is the chain that grabs IL-13 first.
IL13RA1 (interleukin-13 receptor alpha1) is a type I cytokine receptor subunit that binds IL-13 with high affinity. It is the primary ligand-binding component of the interleukin-13 receptor complex and is essential for recruiting IL4R. The mouse Il13ra1 gene has been characterized, providing a model for studying its regulation and function.
IL4R: the shared signaling chain
In simple terms: IL4R is the partner chain that completes the receptor and sends signals inside the cell.
IL4R (interleukin-4 receptor alpha) is a common subunit shared with the type I IL-4 receptor. In the interleukin-13 receptor complex, IL4R does not bind IL-13 directly but is recruited after IL-13 binds IL13RA1, forming a ternary complex that activates JAK kinases and downstream STAT6. IL4R is the target of dupilumab, which blocks both IL-4 and IL-13 signaling.
Ternary complex assembly and structural basis
In simple terms: The two chains come together only when IL-13 is present, like a lock that needs a key to assemble.
Structural studies show that IL-13 binding to IL13RA1 creates a composite surface that engages IL4R, forming a 1:1:1 ternary complex. This stepwise assembly ensures signaling specificity and explains how a single complex can mediate pleiotropic responses to IL-4 and IL-13. The complex is stabilized by extensive electrostatic and hydrophobic interactions between the two receptor chains and the cytokine.
Membrane organization and associated proteins
In simple terms: The receptor sits in the cell membrane and interacts with other proteins to fine-tune signaling.
The interleukin-13 receptor complex is embedded in the plasma membrane and associates with JAK family kinases (JAK1, JAK2, TYK2) and IRS-1/2 adaptor proteins. These interactions link the complex to STAT6 and PI3K/AKT pathways. In cholangiocytes, signaling through this complex regulates TMEM16A expression and biliary secretion.
Key Genes Involved in GO:0005898 interleukin-13 receptor complex
The following genes encode the subunits, signaling effectors, and regulatory proteins of the interleukin-13 receptor complex.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL13RA1 | Primary IL-13 binding subunit of the receptor complex | Knockout reduces IL-13 signaling; target for selective inhibition. |
| IL4R | Shared signaling subunit; recruits JAKs and activates STAT6 | Target of dupilumab; mutations affect allergy and asthma. |
| IL13 | Ligand that binds IL13RA1 and triggers complex assembly | Overexpression models mimic allergic inflammation. |
| IL4 | Cytokine that shares IL4R and cross-regulates the complex | Dual targeting with IL-13 in type 2 diseases. |
| JAK1 | Kinase that phosphorylates STAT6 downstream of the complex | Inhibitors block IL-13 signaling; relevant in atopic dermatitis. |
| JAK2 | Kinase associated with IL4R; activates STAT and IRS pathways | Mediates hematopoietic and tissue-specific effects. |
| TYK2 | Kinase that contributes to IL-13 receptor signaling | Modulates STAT6 activation in immune cells. |
| STAT6 | Transcription factor activated by the complex; drives type 2 genes | Knockout abolishes IL-13-induced mucus and IgE responses. |
| IRS1 | Adaptor protein linking the complex to PI3K/AKT | Regulates metabolic and survival signals. |
| IRS2 | Adaptor protein in IL-13 receptor signaling | Modulates insulin sensitivity and inflammation. |
| TMEM16A | Chloride channel upregulated by IL-13 receptor signaling in cholangiocytes | Regulates biliary secretion; knockout models show ductal dysfunction. |
| CD206 | Mannose receptor on IL-4Rα+ macrophages | Marker of macrophages driving cardiac remodeling. |
| BMPR2 | Bone morphogenetic protein receptor interacting with eosinophil cationic proteins | Links IL-13 inflammation to vascular calcification. |
| FCER1A | High-affinity IgE receptor subunit; downstream of type 2 cytokines | Marker of allergic responses modulated by IL-13. |
| POSTN | Periostin; extracellular matrix protein induced by IL-13 | Biomarker of fibrosis and remodeling. |
| MUC5AC | Mucin gene induced by IL-13 via STAT6 | Readout of goblet cell metaplasia in asthma models. |
| CCL17 | Chemokine induced by IL-13 in atopic dermatitis | Biomarker of skin inflammation. |
| SOCS1 | Negative regulator of JAK-STAT signaling downstream of the complex | Overexpression dampens IL-13 responses. |
How Is interleukin-13 receptor complex Regulated?
The interleukin-13 receptor complex is regulated at multiple levels. Ligand availability (IL-13 and IL-4) controls assembly. Receptor expression is modulated by cytokines and transcription factors, including STAT6 itself, creating feedback loops. Negative regulators such as SOCS proteins and phosphatases attenuate JAK-STAT signaling. IL-13Rα2, a decoy receptor, sequesters IL-13 and prevents complex formation. In disease, dupilumab blocks IL4R and thereby inhibits signaling through both type I IL-4 and interleukin-13 receptor complexes. Additionally, eosinophil-derived cationic proteins can interact with BMP receptors, indirectly influencing vascular calcification in the context of IL-13-driven inflammation.
interleukin-13 receptor complex and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL4R | Atopic dermatitis, asthma | IL4R knockout or point-mutation in keratinocytes and T cells. |
| IL13RA1 | Allergic inflammation, cholangiocyte dysfunction | IL13RA1 knockout in cholangiocytes and airway epithelium. |
| IL13 | Asthma, fibrosis | IL13 overexpression in lung and skin. |
| CD206/IL4Rα | Ischemic cardiomyopathy | Macrophage-specific IL4R knockout in mouse models. |
| TMEM16A | Biliary secretion defects | TMEM16A knockout or knock-in in cholangiocytes. |
Atopic dermatitis and asthma
The interleukin-13 receptor complex is a key driver of type 2 inflammation in atopic dermatitis and asthma. IL-13 and IL-4 signal through this complex to induce IgE class switching, mucus production, and skin barrier dysfunction. Dupilumab, which blocks IL4R, is highly effective but has been associated with rare cutaneous T cell lymphoma in patients with atopic dermatitis, underscoring the need for careful monitoring.
Cholangiocyte dysfunction and biliary disease
Signaling through the interleukin-4 and interleukin-13 receptor complexes regulates cholangiocyte TMEM16A expression and biliary secretion. Dysregulation may contribute to cholestatic liver diseases. This highlights a non-immune role for GO:0005898 in epithelial physiology.
Cardiac remodeling and ischemic cardiomyopathy
CD206+IL-4Rα+ macrophages, which respond to IL-4 and IL-13 via the interleukin-13 receptor complex, drive adverse cardiac remodeling in ischemic cardiomyopathy. Targeting these macrophages or their receptor signaling may improve outcomes after myocardial infarction.
Vascular calcification and atherosclerosis
Eosinophil cationic proteins bind BMP receptors and promote vascular calcification, a process linked to IL-13-driven inflammation. The interleukin-13 receptor complex may indirectly influence this crosstalk, suggesting a role in atherogenesis.
From interleukin-13 receptor complex-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does IL13RA1 loss abolish IL-13 signaling? | IL13RA1 knockout cell lines and mice. |
| How do point mutations in IL4R affect dupilumab binding? | IL4R point-mutation knock-in models. |
| Can tagged IL13RA1 track receptor trafficking? | Knock-in of fluorescent or epitope tags at the endogenous locus. |
| Does overexpression of IL-13 drive fibrosis? | IL13 overexpression transgenic models. |
| What is the role of IL-4Rα in cardiac macrophages? | Macrophage-specific IL4R knockout in ischemic cardiomyopathy models. |
| Does TMEM16A mediate IL-13-induced biliary secretion? | TMEM16A knockout or overexpression in cholangiocytes. |
How to Study the interleukin-13 receptor complex Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss of receptor subunit function | Validate IL13RA1/IL4R dependency. |
| Point mutation | Specific residue contributions to binding/signaling | Map IL-13/IL4R interfaces. |
| Knock-in tagging | Receptor localization and trafficking | Track endogenous complex assembly. |
| RNA-seq | Transcriptional changes downstream of the complex | Identify STAT6 target genes. |
| Proteomics | Protein interactions and modifications | Discover novel complex components. |
| Flow cytometry | Surface expression and immune cell phenotypes | Quantify CD206+ macrophages. |
| Organoid assays | Epithelial secretion and barrier function | Study cholangiocyte TMEM16A regulation. |
| Animal models | In vivo disease phenotypes | Test therapeutic targeting of IL-4Rα. |
CRISPR knockout and point-mutation screens
CRISPR-Cas9 knockout of IL13RA1 or IL4R can validate their essential roles in IL-13 signaling. Point mutations can dissect binding interfaces and signaling motifs, as shown by structural studies of the IL-4/13 system. These approaches are complemented by library screening to identify modifiers of receptor function.
Transcriptomics and proteomics
RNA-seq after IL-13 stimulation reveals downstream transcriptional programs, including STAT6 targets such as MUC5AC and CCL17. Proteomics can identify associated proteins and post-translational modifications of the receptor complex.
Imaging and flow cytometry
Fluorescently tagged IL13RA1 or IL4R knock-in cells allow real-time tracking of receptor assembly and internalization. Flow cytometry can quantify surface expression and macrophage markers like CD206.
Functional assays in organoids and animal models
Cholangiocyte organoids and mouse models of asthma or cardiac ischemia are used to test the physiological consequences of receptor manipulation. These models bridge molecular findings to disease phenotypes.
How CRISPR Can Be Used to Study GO:0005898 interleukin-13 receptor complex
Knockout
CRISPR knockout of IL13RA1 or IL4R abolishes interleukin-13 receptor complex function, providing a clean background to test downstream signaling and disease contributions. For example, IL4R knockout in macrophages can reveal their role in cardiac remodeling.
Point Mutation
Point mutations can be introduced to disrupt specific binding residues or signaling motifs. This is valuable for understanding how IL-13 engages IL13RA1 and how IL4R is recruited, as revealed by structural studies.
Knock-in
Knock-in of tags (e.g., GFP, HA) at the endogenous IL13RA1 or IL4R locus allows visualization and immunoprecipitation of the complex without overexpression artifacts. This approach supports live-cell imaging and proteomic analysis.
Overexpression
Overexpression of IL13 or the receptor subunits can mimic pathological states such as allergic inflammation or fibrosis. These models are useful for testing inhibitors and for studying gain-of-function phenotypes.
How EDITGENE Supports interleukin-13 receptor complex Research
Researchers studying interleukin-13 receptor complex-related genes often need to determine whether a candidate gene is causally involved in receptor assembly, signaling, or disease. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models, enabling rigorous functional validation.
Contact EDITGENE today to design your custom CRISPR model for interleukin-13 receptor complex research.
Frequently Asked Questions About interleukin-13 receptor complex
What is the interleukin-13 receptor complex?
It is a cell-surface protein complex (GO:0005898) that binds interleukin-13 and consists of IL13RA1 and IL4R chains.
What genes are involved in the interleukin-13 receptor complex?
The core genes are IL13RA1 and IL4R; signaling involves JAK1, JAK2, TYK2, STAT6, and IRS1/2.
What is the function of GO:0005898?
It mediates IL-13 and IL-4 signaling, driving type 2 immune responses, mucus production, and tissue remodeling.
How is the interleukin-13 receptor complex assembled?
IL-13 binds IL13RA1 first, then recruits IL4R to form a ternary signaling complex.
What diseases are associated with the interleukin-13 receptor complex?
Asthma, atopic dermatitis, cholangiocyte dysfunction, cardiac remodeling, and lymphoma risk under dupilumab therapy.
What is the role of IL4R in the interleukin-13 receptor complex?
IL4R is the shared signaling subunit that activates JAK-STAT pathways and is the target of dupilumab.
How can I study the interleukin-13 receptor complex using CRISPR?
Knockout, point-mutation, knock-in, and overexpression models can dissect subunit function and disease relevance.
Is the interleukin-13 receptor complex involved in cardiac disease?
Yes, CD206+IL-4Rα+ macrophages drive adverse cardiac remodeling in ischemic cardiomyopathy.
What is the link between the interleukin-13 receptor complex and cholangiocytes?
Signaling through the complex regulates TMEM16A expression and biliary secretion.
What model systems are available for interleukin-13 receptor complex research?
Cell lines, organoids, and mouse models with CRISPR edits are widely used.
Conclusion
The interleukin-13 receptor complex (GO:0005898) is a central signaling hub for IL-13 and IL-4, with critical roles in allergy, tissue remodeling, and organ physiology. Its two-chain architecture and stepwise assembly provide a paradigm for cytokine receptor pleiotropy. Dysregulation is linked to asthma, atopic dermatitis, cholangiocyte dysfunction, and cardiac disease, making it a prime therapeutic target. CRISPR-based models are indispensable for dissecting the complex's function and for validating new drug targets. EDITGENE offers end-to-end services to accelerate this research, from knockout and point-mutation models to library screening and bioinformatics.
References
- 1. Junttila IS. 2018. Tuning the Cytokine Responses: An Update on Interleukin (IL)-4 and IL-13 Receptor Complexes.. Front Immunol 9:888 PMID: 29930549
- 2. LaPorte SL et al.. 2008. Molecular and structural basis of cytokine receptor pleiotropy in the interleukin-4/13 system.. Cell 132(2):259-72 PMID: 18243101
- 3. Harb H et al.. 2020. Mechanisms of Dupilumab.. Clin Exp Allergy 50(1):5-14 PMID: 31505066
- 4. Wang Q et al.. 2025. CD206(+)IL-4Rα(+) Macrophages Are Drivers of Adverse Cardiac Remodeling in Ischemic Cardiomyopathy.. Circulation 152(4):257-273 PMID: 40308203
- 5. Lavin L et al.. 2025. Cutaneous T Cell Lymphoma Following Dupilumab Therapy in Patients with Atopic Dermatitis: Clinical Review and Recommendations.. Am J Clin Dermatol 26(5):723-731 PMID: 40418285
- 6. Meng Z et al.. 2023. Cationic proteins from eosinophils bind bone morphogenetic protein receptors promoting vascular calcification and atherogenesis.. Eur Heart J 44(29):2763-2783 PMID: 37279475
- 7. Dutta AK et al.. 2020. Signaling through the interleukin-4 and interleukin-13 receptor complexes regulates cholangiocyte TMEM16A expression and biliary secretion.. Am J Physiol Gastrointest Liver Physiol 318(4):G763-G771 PMID: 32090602
- 8. Osawa M et al.. 2000. Characterization of the mouse interleukin-13 receptor alpha1 gene.. Immunogenetics 51(11):974-81 PMID: 11003391
